Unión Europea - español - EMA (European Medicines Agency)

provepharm sas - cloruro de metiltioninio - methemoglobinemia - todos los demás productos terapéuticos - tratamiento sintomático agudo de metahemoglobinemia inducida por productos químicos y medicinales. methylthioninium cloruro de proveblue está indicado en adultos, niños y adolescentes (de 0 a 17 años de edad).

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

vetviva richter gmbh - pentobarbital sodico - soluciÓn inyectable - pentobarbital sodico 400 - pentobarbital - bovino; caballos; porcino; perros; gatos; conejos; palomas; ponis; aves de corral; ratas; ratones; visones; cobayas; hámsteres; aves; lagartos; liebres; ranas; serpientes; tortugas terrestres; turones

Unión Europea - español - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - neoplasias de la mama - agentes antineoplásicos - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Unión Europea - español - EMA (European Medicines Agency)

roche registration gmbh - mosunetuzumab - linfoma, folicular - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ever valinject gmbh - cabazitaxel - concentrado para soluciÓn para perfusiÓn - 60 mg inyectable 6 ml - cabazitaxel 10 mg - cabazitaxel

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios biomedipharma s.l. - famotidina - comprimido - 20 mg - famotidina 20 mg - famotidina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios biomedipharma s.l. - famotidina - comprimido - 40 mg - famotidina 40 mg - famotidina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios biomedipharma s.l. - famotidina - comprimido - 20 mg - famotidina 20 mg - famotidina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios biomedipharma s.l. - famotidina - comprimido - 40 mg - famotidina 40 mg - famotidina

Unión Europea - español - EMA (European Medicines Agency)

takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - agentes antineoplásicos - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.